Abstract:A novel formulation containing polyvinylpyrrolidone (PVP) K-30-coated norcantharidin (NCTD) chitosan nanoparticles (PVP-NCTD-NPs) was prepared by ionic gelation between chitosan and sodium tripolyphosphate. The average particle size of the PVP-NCTD-NPs produced was 140.03 +/- 6.23 nm; entrapment efficiency was 56.33% +/- 1.41%; and drug-loading efficiency was 8.38% +/- 0.56%. The surface morphology of NCTD nanoparticles (NPs) coated with PVP K 30 was characterized using various analytical techniques, including X-ray diffraction and atomic force microscopy. NCTD and its metabolites were analyzed using a sensitive and specific liquid chromatography-tandem mass spectrometry method with samples from mice and rats. The results indicated the importance of the PVP coating in controlling the shape and improving the entrapment efficiency of the NPs. Pharmacokinetic profiles of the NCTD group and PVP-NCTD-NP group, after oral and intravenous administration in rats, revealed that relative bioavailabilities were 173.3% and 325.5%, respectively. The elimination half-life increased, and there was an obvious decrease in clearance. The tissue distribution of NCTD in mice after the intravenous administration of both formulations was investigated. The drug was not quantifiable at 6 hours in all tissues except for the liver and kidneys. The distribution of the drug in the liver and bile was notably improved in the PVP-NCTD-NP group. The metabolites and excretion properties of NCTD were investigated by analyzing rat feces and urine samples, collected after oral administration. A prototype drug and two metabolites were found in the feces, and seven metabolites in the urine. The primary elimination route of NCTD was via the urine. The quantity of the parent drug eliminated in the feces of the PVP-NCTD-NP group, was 32 times greater than that of the NCTD group, indicating that the NPs dramatically increased the reduction quantity from liver to bile. We conclude that PVP-NCTD-NPs are an adequate formulation for enhancing the absorption of NCTD, and significantly improving therapeutic effects targeting the hepatic system. Decarboxylation and hydroxylation were the dominant metabolic pathways for NCTD. Metabolites were mainly excreted into rat kidney and finally into urine.

Liquid chromatography–tandem mass spectrometry evaluation of the pharmacokinetics of a diacid metabolite of norcantharidin loaded in folic acid-targeted liposomes in mice

Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo.

Folic Acid Modified Cell Membrane Capsules Encapsulating Doxorubicin and Indocyanine Green for Highly Effective Combinational Therapy in Vivo.

[Studies on the Liver Targeting of Norcantharindin Microemulsion].

Determination of Norcantharidin in Mouse Tissues by Liquid Chromatography Coupled to Tandem Mass Spectrometry and its Tissue Distribution Study

Study on the Distribution and Liver Targeting of Norcantharidin Nanoparticles in Mice

Determination and pharmacokinetic study of norcantharidin in human serum by HPLC-MS/MS method.

Preparation and characterization of norcantharidin liposomes modified with stearyl glycyrrhetinate.

Preclinical evaluations of Norcantharidin liposome and emulsion hybrid delivery system with improved encapsulation efficiency and enhanced antitumor activity

Targeted acid-labile conjugates of norcantharidin for cancer chemotherapy

An Investigation on Liver-Targeting Microemulsions of Norcantharidin.

Liposomal Nanodrug Based on Norcantharidin Derivative for Increased in Vivo Activity

Synthesis, in Vitro and in Vivo Evaluation of New Norcantharidin-Conjugated Hydroxypropyltrimethyl Ammonium Chloride Chitosan Derivatives As Polymer Therapeutics

Pharmacokinetics, Tissue Distribution, and Metabolites of a Polyvinylpyrrolidone-Coated Norcantharidin Chitosan Nanoparticle Formulation in Rats and Mice, Using LC-MS/MS

Studies on Pharmacokinetics of Lactosyl-norcantharidin Nanoparticals in Rats

Study on Pharmacokinetic Profile of PVP-coated Norcantharidin-Chitosan Nanoparticles in Rats by HPLC-MS/MS

Strategies for Solubility and Bioavailability Enhancement and Toxicity Reduction of Norcantharidin

Dihydroartemisinin Loaded Nanostructured Lipid Carriers (DHA-NLC): Evaluation of Pharmacokinetics and Tissue Distribution after Intravenous Administration to Rats.

Co-delivery of daunorubicin and homoharringtonine in folic acid modified-liposomes for enhancing therapeutic effect on acute myeloid leukemia

Studies on Preparation and Drug Release Characteristics of Norcantharidin Liposomes in Vitro

Twin Derivatization Strategy for High-Coverage Quantification of Free Fatty Acids by Liquid Chromatography-Tandem Mass Spectrometry.